Shares of Nektar Therapeutics (NASDAQ:NKTR) rose 1.1% on Wednesday . The company traded as high as $17.79 and last traded at $17.70, with a volume of 513,304 shares traded. The stock had previously closed at $17.51.

NKTR has been the topic of a number of recent analyst reports. Piper Jaffray Cos. reissued a “buy” rating and issued a $17.00 price objective on shares of Nektar Therapeutics in a research report on Wednesday, May 4th. Brean Capital reissued a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, May 4th. Finally, Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $19.40.

The company has a 50-day moving average price of $16.76 and a 200 day moving average price of $14.73. The company’s market cap is $2.44 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.03. The firm had revenue of $32.77 million for the quarter, compared to analysts’ expectations of $34.17 million. During the same quarter in the prior year, the company posted ($0.40) EPS. The business’s revenue was up 44.6% on a year-over-year basis. On average, equities research analysts anticipate that Nektar Therapeutics will post ($1.11) EPS for the current year.

In related news, CAO Jillian B. Thomsen sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $15.09, for a total transaction of $1,509,000.00. Following the sale, the chief accounting officer now directly owns 106,809 shares of the company’s stock, valued at approximately $1,611,747.81. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Chess sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $14.10, for a total transaction of $70,500.00. The disclosure for this sale can be found here.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.